Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

Featured Releases

December 06, 2025 08:00 ET | Source: Costco Wholesale Canada Ltd

Canada’s Tenth Costco Business Centre is now open in East Gwillimbury

COSTCO BUSINESS CENTRE IS NOW OPEN IN EAST GWILLIMBURY - 240 JOBS CREATED, THOUSANDS OF UNIQUE ITEMS TAILORED TO BUSINESS NEEDS
Read More
December 06, 2025 07:00 ET | Source: Mutuum Finance

DeFi Crypto Mutuum Finance Prepares for 20% Price Increase as Phase 6 Nears Completion

DUBAI, United Arab Emirates, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) is approaching a major milestone as Phase 6 of its presale nears completion, bringing the project closer to its...
Read More

December 06, 2025 08:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive announces deep interventional use of clonoSEQ across abstracts at ASH
December 06, 2025 08:30 ET | Source: SNS Insider pvt ltd

Tele-intensive Care Unit Market Size to Reach USD 11.96 Billion by 2032; Growing Advancements in Technology to Propel Market Growth Globally – SNS Insider

Growing adoption of AI enabled remote monitoring and strong demand for critical care efficiency propel tele-intensive care unit market worldwide.
December 06, 2025 08:28 ET | Source: SNS Insider pvt ltd

Lithium-ion (Li-ion) Battery Market Size to Surpass USD 250.04 Billion by 2033 | Research by SNS Insider

Global Li-Ion Battery Market Size, Share & Trends Analysis Report, By Product Type, By Application, By Region and Global Forecast for 2026-2033
December 06, 2025 08:05 ET | Source: Io Therapeutics, Inc.

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

Io Therapeutics announced at the American Society of Hematology studies of their RXR agonist IRX4204 in combination with CAR-T cells for multiple myeloma
December 06, 2025 08:05 ET | Source: Arvinas Inc.

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma...
December 06, 2025 08:00 ET | Source: Disc Medicine Inc

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use ...
December 06, 2025 08:00 ET | Source: Costco Wholesale Canada Ltd

Canada’s Tenth Costco Business Centre is now open in East Gwillimbury

COSTCO BUSINESS CENTRE IS NOW OPEN IN EAST GWILLIMBURY - 240 JOBS CREATED, THOUSANDS OF UNIQUE ITEMS TAILORED TO BUSINESS NEEDS
December 06, 2025 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

Aptose’s Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population
December 06, 2025 08:00 ET | Source: SNS Insider pvt ltd

Carbon Credit Trading Platform Market Size to Exceed USD 1513.44 Million by 2033, at 25% CAGR | SNS Insider

Carbon Credit Trading Platform Market Size, Share & Trends Analysis Report, By Type, System Type, End-use, Region and Global Forecast from 2026-2033
December 06, 2025 08:00 ET | Source: Bicara Therapeutics Inc.

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study...

1 2 ...314374